Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

EPS-$0.47Miss by $0.04
EPS estimate-$0.43

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$129.2M
EPS estimate-$0.55

Financials

Q4 2025

Income statement

See full
Operating income-$56.0M-22.9%
Net income-$50.2M-26.6%
EPS (diluted)-$0.48-14.3%

Balance sheet

See full
Cash & equivalents$61.1M+46.8%
Total debt$4.0M-15.8%
Total equity$522.3M+13.7%
Total assets$552.6M+13.5%

Cash flow

See full
Operating cash flow-$38.6M-43.2%
CapEx$73.0K-73.4%
Free cash flow-$38.7M-42.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.63B+3.9%
Enterprise value$2.57B+3.2%

Returns & leverage

See full
Return on equity-34.2%-0.2pp
Debt / equity0×0.0×
Current ratio19.9×-0.1×

FAQ

When did Edgewise Therapeutics, Inc. report Q4 2025 earnings?
Edgewise Therapeutics, Inc. (EWTX) reported Q4 2025 earnings on February 26, 2026 before market open.
What were Edgewise Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Edgewise Therapeutics, Inc. reported eps of $-0.47 for Q4 2025.
Did Edgewise Therapeutics, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.43 by $0.04.
How did Edgewise Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 11.9% from $-0.42.
Where can I find Edgewise Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-020108) and the 10-K periodic report (0001104659-26-020112) directly on SEC EDGAR. The filing index links above go to sec.gov.